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AbstrACt
Introduction Epilepsy is one of the most common serious 
brain disorders, characterised by seizures that severely affect 
a person’s quality of life and, frequently, their cognitive and 
mental health. Although most existing work has examined 
chronic epilepsy, newly diagnosed patients present a unique 
opportunity to understand the underlying biology of epilepsy 
and predict effective treatment pathways. The objective of 
this prospective cohort study is to examine whether cognitive 
dysfunction is associated with measurable brain architectural 
and connectivity impairments at diagnosis and whether the 
outcome of antiepileptic drug treatment can be predicted 
using these measures.
Methods and analysis 107 patients with newly 
diagnosed focal epilepsy from two National Health 
Service Trusts and 48 healthy controls (aged 16–65 
years) will be recruited over a period of 30 months. 
Baseline assessments will include neuropsychological 
evaluation, structural and functional Magnetic 
Resonance Imaging (MRI), Electroencephalography 
(EEG), and a blood and saliva sample. Patients will be 
followed up every 6 months for a 24-month period to 
assess treatment outcomes. Connectivity- and network-
based analyses of EEG and MRI data will be carried 
out and examined in relation to neuropsychological 
evaluation and patient treatment outcomes. Patient 
outcomes will also be investigated with respect to 
analysis of molecular isoforms of high mobility group 
box-1 from blood and saliva samples.
Ethics and dissemination This study was approved 
by the North West, Liverpool East Research Ethics 
Committee (19/NW/0384) through the Integrated 
Research Application System (Project ID 260623). Health 
Research Authority (HRA) approval was provided on 
22 August 2019. The project is sponsored by the UoL 
(UoL001449) and funded by a UK Medical Research 
Council (MRC) research grant (MR/S00355X/1). Findings 
will be presented at national and international meetings 
and conferences and published in peer-reviewed 
journals.
trial registration number IRAS Project ID 260623.
IntroduCtIon
background and rationale
Epilepsy is one of the most common serious 
brain disorders; every day in the UK, 87 
people are diagnosed with epilepsy, affecting 
over 600 000 people.1 The condition is char-
acterised by devastating seizures that severely 
impact on a person’s quality of life. Epilepsy 
frequently affects a person’s cognitive and 
mental health,2 and the disorder contributes 
to elevated propensity for depression, suicide 
and sudden and unexpected death compared 
with the general population.3 4 Despite this, 
research into epilepsy has been grossly under-
funded compared with other medical condi-
tions of similar economic, social and personal 
impact.5 The vast majority of existing work in 
strengths and limitations of this study
 ► This will be the first study to prospectively investi-
gate brain structural and physiological architecture 
and connectivity in adults with a new diagnosis of 
focal epilepsy.
 ► The study is expected to provide insights into the 
biology underlying cognitive dysfunction in the 
early stages of human epilepsy, and to lead to 
the development of prognostic markers of future 
pharmacoresistance.
 ► Expected recruitment has been based on records 
of past diagnosis at recruitment sites and while the 
study is expected to recruit well, unexpected un-
der-recruitment is possible and would be a barrier 
to timely completion.
 ► A second potential limitation of this study is the 
potential for participant attrition and loss of pa-
tient follow-up at multiple points over 24 months; 
missing data could impact on the validity of study 
conclusions.
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human studies has been performed in chronic epilepsy. 
Newly diagnosed epilepsy (NDE) is only rarely studied 
despite representing a key point in time to understand 
the underlying biology of the disorder in the absence 
of confounds including antiepileptic drugs (AEDs) and 
long-term seizure effects.6 It is important to understand 
the reasons why people with epilepsy experience cognitive 
problems and seizures after treatment using safe imaging 
technologies from the earliest time point of the disorder. 
If we can understand these reasons in the early stages of 
epilepsy, we may be able to predict which patients will 
continue to experience seizures despite standard drug 
therapy. Patients who will not respond to drug therapy 
could potentially be offered alternative or adjunctive 
treatments, saving time, cost and the experience of unde-
sirable side effects of certain AEDs.
Magnetic Resonance Imaging (MRI) and Electro-
encephalography (EEG) are routinely used to assess 
people with epilepsy. However, the application of these 
brain imaging techniques in the context of standard care 
cannot determine why some patients have cognitive prob-
lems and why others do not, and why some patients do not 
respond to AED therapy while others do. A new direction 
of brain imaging is therefore required, preferably one 
that can be incorporated into the standard clinical evalua-
tion of patients. In patients with longstanding epilepsy the 
study of brain connectivity and networks (how different 
regions of the brain work together by virtue of their 
connectivity) using MRI and EEG has recently provided 
valuable insights into how the brain is structurally and 
physiologically altered in epilepsy.7 8 There is growing 
evidence that aberrant network dynamics are a key part 
of the underlying mechanisms of focal and generalised 
epilepsies.9 State-of-the-art quantitative structural (eg, 
diffusion MRI and tractography approaches), functional 
(eg, resting-state functional MRI (fMRI)), and physio-
logical (eg, EEG) imaging techniques have provided a 
novel way of automatically distinguishing longstanding 
epilepsy patients from healthy controls,10 and predicting 
postoperative treatment outcome in severe epilepsy.11–16 
We propose that these approaches will provide new expla-
nations for the causes of cognitive problems and future 
treatment outcome from the beginning of a patient’s life 
with epilepsy.
Furthermore, mechanistic blood and saliva biomarkers 
could greatly enhance drug discovery by providing novel 
therapeutic targets and enrich trial populations, facil-
itating early surgical evaluation in drug resistance. We 
have soon-to-be-published data suggesting that molec-
ular isoforms of high mobility group Box 1 (HMGB1) 
– a protein critically involved in the initiation of the 
inflammatory cascade in epilepsy –17 have potential as 
a prognostic biomarker. The acetylated, disulfide form 
of HMGB1, which triggers pro-inflammatory cytokine 
release via toll-like receptor 4, has shown pathological 
effects in pre-clinical models of seizures.18 In a parallel 
running study, we are currently studying people with long-
standing epilepsy using MRI and blood serum markers of 
HMGB1 (short title: ‘MRI of inflammation in epilepsy’; 
IRAS project ID 220138; REC reference 17/NW/0342, 
Northwest-Liverpool).
This observational cohort study will be the first to 
prospectively investigate brain structural and physiolog-
ical architecture and connectivity in adults with NDE 
with overarching goals to: (1) understand the neural 
basis of cognitive impairment; and (2) identify why and 
in whom seizures persist despite AED therapy. We will 
recruit adults with a new diagnosis of focal epilepsy and 
perform cognitive assessment and sophisticated anal-
ysis of MRI and EEG data. At the time of scanning and 
neuropsychological evaluation (baseline), all partici-
pants will additionally have blood and saliva extracted. 
Patients will be followed up longitudinally to determine 
their response to AED therapy. MRI/EEG data will be 
used to identify the neural correlates of cognitive impair-
ment and to predict treatment outcome. Data generated 
from extracted blood and saliva samples will also be used 
to predict treatment outcome. To remain consistent 
with our ongoing work that investigates the correlation 
between MRI data in HMGB1 in people with epilepsy, 
we will use an identical approach of data acquisition and 
analysis. This work will be performed in an environment 
with demonstrated excellence in the care of people with 
epilepsy, recruitment of adults with NDE into clinical 
trials and expertise in MRI, EEG, neuropsychological 
and blood serum analysis. The research objectives of the 
proposed work directly address internationally agreed 
research priorities in epilepsy, with potential to provide 
significant insights into the epilepsy phenotype and to 
generate clinically meaningful non-invasive markers of 
treatment outcome.19 20
study objectives and design
The goal of the proposed research is to perform the first 
prospective multi-modal imaging investigation of brain 
architecture and connectivity in adults with a new diag-
nosis of focal epilepsy. The project aims to provide new 
insights into the biology underlying cognitive dysfunc-
tion in the early stages of human epilepsy and develop 
prognostic markers of future pharmacoresistance. The 
research will take place in context of a collaborative 
research and clinical environment that has demonstrated 
excellence in the recruitment and study of patients with 
NDE. The three main objectives are outlined below.
Objective 1
The primary objective is to determine the cognitive pheno-
type associated with NDE and whether cognitive dysfunc-
tion is associated with measurable brain architectural and 
connectivity impairments at diagnosis. We expect that 
patients will be cognitively impaired in the domains of 
memory, sustained attention and executive function; this 
impairment will be reflected in pathological alterations to 
structural and functional neural networks and responses 
to a verbal memory task computed from f/MRI and EEG.
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Objective 2
A secondary objective is to determine whether AED 
treatment outcome can be predicted using multi-modal 
imaging measures of brain architecture and connectivity 
at the point of epilepsy diagnosis. We expect that archi-
tectural and physiological alterations within local and 
networked brain regions can predict patient response to 
pharmacological therapy at diagnosis.
Objective 3
We will determine whether blood serum and saliva derived 
measures of inflammation can predict AED treatment 
outcome in patients with NDE and examine relationships 
between molecular isoforms of HMGB1 and MRI, EEG 
and neuropsychological data.
MEthods And AnAlysIs
study environment
Research will be carried out by the Epilepsy Research 
Group within the Institute of Translational Medicine, 
University of Liverpool (UoL). The group is closely affil-
iated with the Walton Centre Foundation NHS Trust 
(WCFT) from where patients will be recruited, alongside 
the Salford Royal NHS Foundation Trust (SRFT). Both 
WCFT and SRFT will acquire patient EEG data in context 
of standard clinical care; EEG data for healthy controls 
will be acquired at the WCFT. MRI acquisition will be 
performed at the Liverpool Magnetic Resonance Imaging 
Centre (LiMRIC; www. liv. ac. uk/ limric), using a Siemens 
Prisma 3T scanner. Blood/saliva will be extracted from 
participants at LiMRIC and stored at the Liverpool 
University Biobank (LUB) freezer room.
Eligibility criteria
Based on sample size calculations (see below), we will 
recruit 107 people with a new diagnosis of focal epilepsy 
and 48 healthy controls. Inclusion and exclusion criteria 
for patients and controls are outlined below.
Inclusion criteria
Patients with epilepsy
 ► Patients who are attending or have attended clinics at 
WCFT and SRFT who have been diagnosed with focal 
epilepsy (eg, temporal or frontal lobe epilepsy) by a 
neurologist.
 ► Maximum of 3 months since diagnosis.
 ► Between and including the ages 16–65 years.
Healthy controls
 ► No history of neurological or psychiatric illness or 
disease.
 ► Between and including the ages 16–65 years.
 ► No use of drugs or over four units of alcohol consumed 
in the preceding 48 hours.
Exclusion criteria
Patients with epilepsy
 ► Non-epileptic seizures.
 ► Single seizures.
 ► Primary generalised seizures.
 ► Provoked seizures only (eg, alcohol).
 ► Known inflammatory neurological condition (specifi-
cally multiple sclerosis or sarcoidosis).
 ► Acute symptomatic seizures (eg, acute brain haemor-
rhage or brain injury).
 ► Progressive neurological disease (eg, known brain 
tumour).
 ► Previous neurosurgery.
 ► Concomitant infection.
 ► Any other significant morbidity (physicians 
discretion).
Healthy controls
 ► Any neurological disease or illness.
 ► Drug use or five or more units of alcohol consumed in 
the preceding 48 hours.
MRI criteria
All participants will be examined by a radiographer and 
will complete a safety checklist that is designed to iden-
tify whether a participant has internal bodily metal, which 
could pose a hazard during MRI scanning. All removable 
bodily metal will be removed before scanning. Standard 
MRI exclusion criteria include:
 ► Internal bodily metal.
 ► Cardiac pacemaker or defibrillator.
 ► Cochlear, otologic or ear implant.
 ► Any implant held in place by a magnet.
 ► Implanted catheter, clamp, clips, valves or other metal.
 ► Presence or history of claustrophobia.
 ► Pregnancy.
 ► Unremovable bodily piercings or other metal.
sample size calculation
Taking into account that roughly 2/3 of patients with 
NDE are expected to achieve 12 months of remission 
within 2 years21 22 approximately 72 patients with NDE 
(48/24 patients who achieve/do not achieve remission) 
and 48 controls are required to detect large effect sizes 
of 1.2 or above (large effects sizes are supported by our 
previous findings),23 with power 90% and significance 
level of 0.001. Given the nature of the study and that 
a panel of biomarkers will be tested, a low significance 
level has been chosen to control for the false discovery 
rate (type I error).24 In the calculations we have also 
accounted for the ratio 2:1 for patients with NDE who 
achieve/do not achieve remission. After taking into 
account that ~25% patients will present with brain 
lesions,25 26 and considering a potential attrition rate of 
10%, a total of 107 patients with a new diagnosis of focal 
epilepsy will be recruited. Our experience leading multi-
centre clinical trials in patients with NDE,27–29 and consid-
ering the inclusion criteria, is that it will take 30 months 
to recruit this number of patients from the WCFT and 
SRFT. The proposed sample size will also provide enough 
power to detect large effect sizes between NDE patients 
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Figure 1 The recruitment process. EEG, electroencephalography; PIS, participant information sheet; RT, research team; SRFT, 
Salford Royal NHS Foundation Trust; UoL, University of Liverpool; WCFT, Walton Centre Foundation NHS Trust.
and controls with respect to neuropsychological perfor-
mance30 and therefore make it possible to address Objec-
tive 1.
recruitment process
A summary of the recruitment process is shown in 
figure 1. We will recruit participants attending WCFT and 
SRFT epilepsy clinics according to the aforementioned 
inclusion criteria. A clinical member of the research team 
(RT) (ie, consultant neurologist, epilepsy nurse) will 
enquire whether eligible patients would be interested in 
participating in this study at the time of consultation in 
outpatient clinics. If so, the patient will be provided with 
an information sheet and consent form and allowed at 
least 48 hours to consider participation. The patient will 
then be contacted by telephone by a member of the RT to 
discuss participation, and if the patient would still like to 
participate, an appointment will be made for the investi-
gations. Patients will bring their signed and dated consent 
forms with them to their appointment. A member of the 
RT will confirm consent for each patient.
Healthy controls will be recruited from an existing 
volunteer register and advertisements placed on UoL 
notice boards. The recruitment of controls will be age-, 
sex- and educationally matched. If we struggle to recruit 
educationally matched controls, we will advertise to the 
local (Liverpool) community using online classified 
advertisements and community websites. A member of 
the RT will determine eligibility and interest of potential 
controls. Volunteers will be provided with a study informa-
tion sheet and consent form via email. Eligible volunteers 
will be given an appointment for investigation. Control 
volunteers will bring their signed and dated consent 
forms with them to their appointment. A member of the 
RT will confirm consent for each control volunteer.
All participants will receive reimbursement of £100 for 
their participation in this study.
Participant withdrawal
Participants may withdraw their participation in this study 
at any time by contacting the RT. If participants with-
draw from the study, information that has already been 
obtained will be kept in minimum personally identifiable 
format to ensure that their privacy rights are safeguarded.
outcomes
The primary treatment outcome variable is seizure 
outcome 2 years after diagnosis, which is a reliable time 
point and frequently used marker of pharmacoresis-
tance.22 31 Seizure freedom will be defined as a period 
of no seizures within the preceding 12 months at 2-year 
outcome, which aligns with current UK driving legis-
lation.32 The number and type of seizures experienced 
since the last follow-up and current medication will be 
recorded by telephone by an epilepsy specialist nurse 
using a brief questionnaire adapted from the Standard 
and New Antiepileptic Drugs (SANAD) II clinical trial. 
In order to address Objective 1, we require control 
imaging and cognitive data from healthy participants, 
which will be compared with corresponding patient 
data. Based on previous findings,25 26 ~25% of patients 
with NDE recruited are expected to have an identifiable 
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Figure 2 Organisation of the study phases.
lesion. Although the primary focus of this study will be on 
patients with MRI-negative NDE, as these represent the 
large majority of cases, having imaging and neuropsycho-
logical data from patients with lesional NDE will allow us 
to investigate whether the contribution of aberrant brain 
architecture and function is more significant than gross 
brain lesions for the prediction of cognitive dysfunction 
and treatment outcome. In brief, outcomes will consist of 
statistically significant differences in structural and func-
tional brain connectivity and cognition between patients 
and controls as well as between patients with and without 
seizures 2 years after diagnosis.
study phases
The study will last 5 years – from 1 October 2019 to 1 
October 2024 – and be split into four phases. Five years 
are necessary given recruitment and follow-up objec-
tives (Objective 2): we require a recruitment period long 
enough to recruit a sufficient number of patients with 
NDE and a follow-up period long enough to establish 
likely seizure remission/pharmacoresistance. Figure 2 
graphically illustrates the organisation of study phases.
Phase 1
[Ph1; month 1–3] is an initial 3-month period dedicated 
to project set-up, optimisation of the MRI protocol and 
psychologist training for proficient administration of the 
neuropsychology battery. MRI optimisation will include 
technical development, MRI scanning of phantoms and 
human volunteers to ensure the MRI sequences are 
adequate for the study.
Phase 2
[Ph2; month 4–33] is a 30-month period that includes 
participant recruitment, and MRI, EEG, neuropsycholog-
ical and blood serum and saliva data acquisition for all 
recruited participants. The imaging data acquired for all 
patients and controls will be processed using image anal-
ysis techniques throughout Ph2. The final 3 months of 
Ph2 will be dedicated to the analysis of imaging markers 
of cognitive dysfunction to address Objective 1 once all 
imaging and neuropsychological data is collected (Ph2b).
Phase 3
[Ph3; month 10–57] is a 48-month patient follow-up 
period during which time all seizure outcome informa-
tion will be recorded by telephone by a research nurse 
at the WCFT. Standardised assessment of patient seizure 
outcomes will be performed at 6, 12, 18 and 24 months 
after enrolment into the study. Although the 24-month 
assessment is the primary outcome time point for this 
study, we will endeavour to monitor patient status beyond 
the life of the grant award.
Phase 4
[Ph4; month 55–60] is the final 6-month period dedi-
cated to addressing Objectives 2 and 3 when all outcome 
data are available using multivariate statistics and prog-
nostic modelling.
data acquisition
In total, we will perform 155 MRI, EEG, neuropsycholog-
ical and blood/saliva sample investigations. Neuropsy-
chological, MRI and blood/saliva sample data collection 
will be performed at the Liverpool Magnetic Resonance 
Imaging Centre (LiMRIC, Research Technology Building, 
UoL). The MRI protocol will include clinical sequences 
for diagnostic appraisal (see below), and a consultant 
neuroradiologist will review the scans of each participant 
as per standard clinical protocol. EEG data collection will 
take place at the WCFT and SRFT. Patients identified at 
SRFT will be transported from Manchester to Liverpool. 
A summary of the procedures for each participant is 
shown of table 1.
LiMRIC
Consent. Informed consent will be taken before 
assessments.
Neuropsychology. We will use a computerised neuro-
psychological battery (lasting up to 2 hours, including 
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Table 1 Summary of procedures
Procedure Location Duration Number of examinations
1.Consent Quiet assessment room, 
UoL
10 min 1
2.Neuropsychological evaluation Quiet assessment room, 
UoL
2 hours, including comfort breaks 1
3.MRI LiMRIC, UoL 1 hour, including safety 
examination and set-up
1
4.Blood/saliva extraction UoL 5 min 1
5.EEG Neurophysiology, WCFT 
and SRFT
1 hour, including set-up 1
6.Telephone questionnaire Home 5 min 4 (6, 12, 18 and 24 months 
after scans)
EEG, electroencephalography; LiMRIC, Liverpool Magnetic Resonance Imaging Centre; MRI, Magnetic Resonance Imaging; SRFT, Salford 
Royal NHS Foundation Trust; UoL, University of Liverpool; WCFT, Walton Centre Foundation NHS Trust.
comfort breaks) that we have shown to be sensitive to 
cognitive deficits in people with NDE.30 33 These will 
include components from the Wechsler Memory Scale 
Fourth Edition (WMS-IV),34 Wechsler Adult Intelligence 
Scale Fourth Edition (WAIS-IV),33 34 Delis-Kaplan Execu-
tive Function System (D-KEFS),35 36 Patient Health Ques-
tionnaire 9 (PHQ-9),37 Generalised Anxiety Disorder 
7 (GAD-7),38 The A-B Neuropsychological Assessment 
Schedule (ABNAS)39 and Quality of Life in Epilepsy 
(QOLIE-31) scale.40 More specifically these assessment 
tools will be used to evaluate:
 ► Auditory memory through story recall and recall of 
verbal pairs (WMS-IV).
 ► Visual memory through reproduction of drawings 
and recall of designs (WMS-IV).
 ► Working memory and attention through digit span 
and arithmetic tasks (WAIS-IV).
 ► Processing speed through a coding and symbol search 
task (WAIS-IV).
 ► Psychomotor speed through a finger tapping and 
visual reaction time task.
 ► Executive functioning through verbal fluency and 
colour-word interference tasks (D-KEFS).
 ► Mood including depression (PHQ-9) and anxiety 
(GAD-7).
 ► Perceived cognitive impairment (ABNAS).
 ► Quality of life (QOLIE-31).
MRI scanning. The MRI protocol will be performed on 
a 3T Siemens Prisma MRI at LiMRIC and will consist of 
the following sequences:
 ► Conventional 2D T2-weighted fast spin echo and fast 
fluid attenuated inversion recovery scans, for inci-
dental findings screening, and detection of gross 
pathology (together with localiser 11:00 min).
 ► 3D T1-weighted MPRAGE (Magnetization-Prepared 
Rapid Acquisition with Gradient Echo) scan with 
isotropic voxel size of 1 mm × 1 mm × 1 mm (7:30 min).
 ► fMRI verbal memory task scan adapted from Sidhu 
et al.41: whole brain echo planar imaging (EPI) 
sequence, with voxel size of 2 mm × 2 mm × 2 mm, 
Repetition Time (TR)=2.75; 10 concrete nouns shown 
for 3 s in 10 blocks of 30 s followed by a 15 s baseline 
period (fixation cross); participants indicate whether 
each word is pleasant or unpleasant (8:23 min).
 ► Resting-state fMRI with eyes open with relaxed 
fixation on projected crosshair, whole brain EPI 
sequence, with voxel size of 2 mm × 2 mm × 2 mm, 
TR=2.5 (8:02 min).
 ► Diffusion kurtosis imaging (DKI) sequence with 60 
isotropically distributed gradient directions, three b 
values (b=0, 1000 and 2000) and maximum voxel size 
of 2 mm × 2 mm × 2 mm (8:06 min).
Post-scanning task. A verbal recognition task of words 
presented in the fMRI verbal memory task will be 
completed outside the scanner (<7 min).
Blood extraction. Blood will be collected for analysis in 
lithium-heparin bottles or serum separator tubes (9 mL). 
A maximum of 72 mL of blood (3×9 mL vials) will be 
obtained from each participant. Samples will be obtained 
by a healthcare professional trained in phlebotomy. 
A standard operating procedure for blood sampling 
including aseptic technique will be utilised.
Saliva extraction. Samples of unstimulated saliva will be 
collected by soaking a sponge swab in the mouth of each 
participant until the swab is saturated with saliva. The 
swab will be inserted into a collection tube.
WCFT and SRFT
EEG. All participants will undergo a conventional clinical 
EEG, using 19 channels in 10–20 arrangement. Patients 
will be scanned in context of standard care in their 
respective trust (WCFT or SRFT) while controls will be 
scanned at the WCFT. Participant visiting time will last 
approximately 1 hour.
data analysis
All MRI and EEG analysis techniques are automated and 
not subject to investigator bias.
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MRI analysis
The MRI analysis procedures that will be carried out 
include (but will not be exclusive to):
Thalamocortical analysis. Our preliminary (unpublished) 
data have indicated that patients with NDE have structural 
changes in the thalamus. We will use DKI approaches to 
examine thalamic and thalamocortical connectivity. Mean 
DKI values will be obtained from spatially co-registered 
regions-of-interest (ROIs) (principally thalamocortical 
regions) in standard space. We will also apply diffusion42 
and resting-state fMRI43 independent component analysis 
techniques using FSL’s MELODIC (Multivariate Explor-
atory Linear Optimized Decomposition into Indepen-
dent Components) toolbox44 (http:// fsl. fmrib. ox. ac. uk/ 
fsl/ fslwiki/ MELODIC) and in-house MATLAB scripts to 
identify abnormal structural and functional thalamocor-
tical connectivity in patients relative to controls. We will 
also compare patient neuropsychological and treatment 
outcome groups using these approaches.
White matter tracts. Our recent publications have indi-
cated that analysis of white matter tract diffusion has 
significance for predicting postsurgical seizure outcome 
in patients with chronic focal epilepsy12 16 and that DKI 
is more sensitive to tract pathology than diffusion tensor 
imaging in epilepsy.45 As white matter tracts constitute 
the structural connections within brain networks, we will 
determine DKI properties along the length of multi-lobar 
white matter tract bundles, using our recently reported 
methods.45 46
Large-scale functional networks. Using our recently 
described resting-state analysis techniques,23 we will 
identify and analyse features of the major resting-state 
networks, including the fronto-parietal attentional 
network, default mode network, salience network and 
language network. All analyses will be performed using 
the functional connectivity toolbox.47
Graph theory (Connectome). The development of whole 
brain connectomes48 from diffusion MRI data has led 
to successful data-driven approaches to predict surgical 
responsiveness in patients with refractory focal epilepsy 
from members of our group.11 13–15 Connectome 
approaches also support the association between post-
operative seizure control and thalamocortical connec-
tivity.14 Similar methods have been applied to resting-state 
fMRI data to model functional connectome alterations 
in chronic focal epilepsy.49 As per our recent connec-
tomic studies, whole brain structural connectomes will 
be generated for each participant using T1-weighted 
and DKI data. T1-weighted data will be parcellated into 
multiple ROI (nodes) using Freesurfer software (http:// 
freesurfer. net). Structural connectivity between nodes 
will be determined using FSL’s diffusion toolbox (http:// 
fsl. fmrib. ox. ac. uk/ fsl/ fslwiki/ FDT) for probabilistic fibre 
tracking applied to diffusion MRI. Structural connec-
tomes will be generated using the Connectome Mapping 
Toolkit (http://www. connectome. ch). We will use graph 
theory to determine global and regional network configu-
ration. Global network ‘small worldness’ will be assessed, 
representing the ratio between average nodal clustering 
coefficients and as network efficiency. Regional clustering 
coefficient, efficiency and centrality will also be calculated 
for key brain areas associated with seizure onset and prop-
agation such as thalamocortical and limbic networks. We 
will generate resting-state functional connectomes using 
a similar approach to structural connectomes. Whereas 
for structural connectomes edges are represented 
by diffusion streamlines and kurtosis diffusion scalar 
metrics, functional connectomes will use fMRI time series 
correlations between each anatomical ROI to generate a 
temporal correlation matrix.
Other network approaches. Using DKI, T1 and resting-state 
fMRI data, we will apply network-based statistics to explore 
network alterations common to subgroups of patients,50 
and machine/deep learning algorithms to classify indi-
vidual patient outcomes.13
Verbal memory fMRI. Following previous work,41 we will 
explore the relationship between memory deficits and 
neural processing of verbal memory using task-based 
fMRI. An event-related analysis (FSL-FEAT) will be used 
to examine the neural correlates of successful subse-
quent memory formation, comparing memory encoding 
networks between patients and controls, as well as between 
seizure-free and drug-resistant epilepsy patients. Between-
group ROI comparisons in temporal and extra-temporal 
regions will also be made with neuropsychological vari-
ables included as covariates into a general linear model. 
We hypothesise that altered neural processing of verbal 
memory will be observed in patients with memory-related 
deficits and that network organisation differences centred 
around temporal regions will be observed in patients with 
drug-resistant epilepsy.
EEG analysis
Resting-state EEG activity will be identified by a trained 
clinical EEG technician. Nodes in EEG networks will be 
defined as electrodes, and a range of measures of inter-
dependence between electrodes will be explored. We 
will apply computer models of network dynamics to rest-
ing-state EEG data.10 In order to address Objective 1 and 
Objective 2, we will analyse EEG network dynamics by 
mirroring the approach we will take with MRI (thalamocor-
tical and connectome analysis); first, we will focus on thal-
amocortical physiological alterations by source-localising 
activity within thalamic and cortical regions and deter-
mine connectivity between regions using dynamic causal 
modelling.51 Second, we will reconstruct resting-state 
EEG connectomes consistent with the resting-state func-
tional MRI approach and determine network-based phys-
iological differences between groups. We will also explore 
the inter-relation between EEG and MRI determined 
connectivity by performing DKI tractography seeded 
from nodes identified as aberrantly connected using EEG 
to determine whether abnormal physiological connec-
tivity is related to abnormal structural connectivity. This 
approach has been adopted in patients with refractory 
epilepsy who underwent stereoelectroencephalography.52
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Blood and saliva sample analysis
In the laboratory, blood samples will be centrifuged 
within 15 min of collection or stored overnight at 4°C 
for centrifugation the following day. 250 µl aliquots will 
then be transferred to appropriate tubes and stored at 
approximately −80°C prior to bioanalysis. Saliva samples 
will be collected into an Eppendorf tube by squeezing the 
saturated swab using a syringe. The sample will be stored 
at −80°C freezer until assay. Blood and saliva samples 
will be analysed for inflammatory markers, HMGB1 and 
brain-specific markers including microRNA. Inflam-
matory marker and HMGB1 expression analysis will be 
undertaken by ELISA and HMGB1 quantification will be 
made by liquid chromatography and mass spectrometry. 
Blood/saliva samples will be stored in the LUB freezer 
room, which is housed in the Research Technology 
Building with LiMRIC.
Statistical analysis
We will explore the discriminatory effect of imaging 
biomarkers when taking into account their correlation 
structure and develop predictive models.
Cognitive dysfunction
Multivariate discriminant techniques will be used to 
identify structural/physiological brain measures that 
significantly differ between controls, patients with NDE 
who are cognitively normal and patients with NDE who 
are cognitively impaired (where impairment is defined 
by patient performance lower than two SD53 than that of 
the group of controls on respective neuropsychological 
tasks). We will also investigate the relationship between 
patient cognitive performance and imaging measures 
of architecture and network connectivity using multi-
variate regression analyses.
Treatment outcome
Multivariate data techniques will be used to determine 
imaging measures that significantly differ between 
controls, patients who achieve remission over 12 months 
within 2 years and patients who do not achieve remis-
sion within the same time period. Embedded multivar-
iate techniques such as least absolute shrinkage and 
selection operator and the support vector machines 
approaches (eg, with radial and polynomial basis func-
tion kernels) will be applied to identify the panel of 
biomarkers with optimal discriminatory ability. For this 
process we will also consider patient demographic and 
clinical data, and presence of brain lesion. The variable 
selection algorithms will take into account the correla-
tion between the variables, as well as variance differ-
ences across groups. To minimise the effect of possible 
over-fitting, penalty terms will be embedded in the vari-
able selection algorithm to take into account model 
complexity. We will develop prognostic models for the 
assessment of outcome at 2 years using multivariate 
discriminant analysis.54 Cross-validation and bootstrap 
techniques will be applied when appropriate.
EthICs And dIssEMInAtIon
Ethical approval
The PI will ensure that the study is conducted in full 
accordance with approved protocols and that agreed 
modifications are disseminated to all relevant parties.
Confidentiality
Procedures for handling, processing, storage and destruc-
tion of your data are compliant with the Data Protection 
Act 1998. All EEG and MRI data will be anonymised prior 
to being exported from the WCFT, SRFT and LiMRIC, 
respectively. Personal information will not be identifiable 
from the imaging data. Names will be replaced with study 
ID numbers (EPINET001, EPINET002, etc), which can 
be backtracked to participant details using a key located 
at LiMRIC and only accessible to the primary care team. 
Storage eppendorfs will be labelled with the unique iden-
tifier only with no other patient information. Similarly, all 
electronic neuropsychological data will be associated with 
study ID numbers. All documents associated with the study 
will be stored securely and only accessible by research 
staff and authorised personnel. Participant recruitment 
data will be monitored through study adoption by the 
National Institute for Health Research (NIHR) portfolio.
Informed consent
All participants will be provided with a research informa-
tion pack describing the nature and goals of the research, 
and study consent form, which must be completed, 
signed and dated. We will not recruit participants who 
lack capacity to provide informed consent (eg, those with 
intellectual disability or dementia). Study consent forms 
will be retained and filed in a locked cupboard in the 
office of the PI. Information packs and consent forms 
will be given to people with epilepsy by a research nurse 
immediately after diagnosis in outpatient clinics. Infor-
mation packs will be sent to healthy control volunteers 
via email or post. All participants will be given consent 
forms to complete at their first scanning appointment 
bring consent forms with them to their appointment for 
MRI and EEG scanning. The RT will the take the partic-
ipant through the information sheet and consent form, 
explaining any aspects of the study that the participant is 
unclear about. Patients and controls will have as long as 
they require to consider their decision to volunteer for 
the research or not. The investigators contact details will 
be provided in the information pack.
Potential benefits and risks
There are no direct benefits to the participant. However, 
participation may lead to improved understanding of the 
aetiology, development and prognosis of epilepsy in the 
future.
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MRI is considered a safe technique and scanning envi-
ronment. The MRI system produces a high magnetic 
field, and it is necessary for the participants to remove all 
ferrometallic objects from their person before entering 
the scanning room. As per routine protocol, clinical 
members of staff screen participants for their suitability 
for scanning and fully debrief them after scanning. The 
MRI scanner is a noisy and confined environment, which 
may cause the participant to feel slight discomfort and 
claustrophobia. During scanning the subject will be moni-
tored from the MRI control room by clinical staff and 
their heart rate continuously monitored. If participants 
feel discomfort, scanning can be discontinued by pressing 
a distress button that the participant will be given before 
entering the scanner.
As indicated in the study information pack, scans will 
be reviewed to make sure that there is no brain pathology. 
Any MRI incidental finding will be reported to a consul-
tant neuroradiologist. If the MRI finding is deemed to 
warrant further investigation, the participant’s General 
Practitioner (GP) may be contacted. The percentage of 
unanticipated clinically serious brain abnormalities in 
healthy people is extremely low.
Venipuncture poses minimal risk of bruising or 
bleeding. All efforts will be made to minimise the risk of 
infection; appropriate training in infection control will 
be undertaken by all healthcare professionals.
There are no potential risks of EEG recordings. Neuro-
psychological evaluation could potentially lead to partic-
ipant fatigue, frustration or emotional disturbance. To 
obviate this, we will provide each participant with suffi-
cient resting time between each assessment.
Patient and public involvement
No patients were directly involved in the design of this 
study. However, all participants will be fully debriefed 
regarding the goals and design of the research and will 
have the option of receiving a letter with a brief summary 
of the results at the end of the study.
dissemination
We aim to produce high-impact peer-reviewed publica-
tions of the results of the study and present findings at 
national and international conferences, with exclusive 
access to the final study data set for a period of 6 years. 
We will target epilepsy (eg, European Congress for 
Epileptology, International Epilepsy Congress, Interna-
tional League Against Epilepsy UK Chapter, American 
Epilepsy Society) and neuroimaging (eg, The Organi-
sation of Human Brain Mapping, International Society 
for Magnetic Resonance in Medicine) conferences. The 
investigators will be involved in preparing manuscripts 
drafts, abstracts, press releases among any other publi-
cations arising from the study and will acknowledge that 
the study was funded by the MRC. For each publication, 
only members of the RT who made a significant intellec-
tual contribution to each piece of work will be consid-
ered as an author. This is in line with journal protocol. 
All authors share responsibility for the contents of the 
submitted manuscript.
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